SITE005-0131

SITE005 (FRA) › SITE005-0131

SITE005-0131

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2026-01-30

completed

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-12-15 (study day 126); relationship: not assessed

mild assessed

Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 120); relationship: RELATED

severe assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-30 (study day 111); relationship: not assessed

mild assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-05 (study day 55); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.